World Equity Group Inc. Acquires New Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

World Equity Group Inc. acquired a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) during the fourth quarter, HoldingsChannel reports. The fund acquired 20,000 shares of the biotechnology company’s stock, valued at approximately $48,000.

A number of other large investors also recently modified their holdings of the company. Peapod Lane Capital LLC purchased a new position in shares of Oramed Pharmaceuticals during the 4th quarter valued at about $550,000. Marquette Asset Management LLC purchased a new position in Oramed Pharmaceuticals in the 4th quarter worth approximately $81,000. XTX Topco Ltd increased its stake in Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares during the period. Murchinson Ltd. increased its stake in Oramed Pharmaceuticals by 0.5% in the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock worth $4,170,000 after purchasing an additional 8,889 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Oramed Pharmaceuticals in the 3rd quarter worth approximately $272,000. 12.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com cut Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 19th.

Oramed Pharmaceuticals Price Performance

Shares of Oramed Pharmaceuticals stock opened at $2.16 on Tuesday. The business’s 50 day simple moving average is $2.33 and its two-hundred day simple moving average is $2.36. The stock has a market capitalization of $87.07 million, a P/E ratio of 19.64 and a beta of 1.66. Oramed Pharmaceuticals Inc. has a one year low of $2.00 and a one year high of $3.67.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.